NCT04690062 is a Phase 4 clinical trial of Brolucizumab-Dbll in Dystrophy, Retinal, sponsored by Benha University.

Who is sponsoring NCT04690062?

NCT04690062 is sponsored by Benha University.

What drugs are being tested in NCT04690062?

Interventions in NCT04690062: Brolucizumab-Dbll.

What condition does NCT04690062 study?

NCT04690062 studies Dystrophy, Retinal.

Is NCT04690062 still recruiting?

NCT04690062 is currently status unknown. Last updated 30 December 2020.

Last reviewed 2020-12-30 · How we verify

NCT04690062

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BEOVU in the Treatment of Dystrophy-related Macular Neovascular Degeneration

Status unknown Phase 4 Last updated 30 December 2020

What this trial tests

Phase 4 trial testing Brolucizumab-Dbll in Dystrophy, Retinal in 20 participants. Status unknown.

Timeline

25 October 2020

Primary endpoint
25 December 2022

30 December 2022

Quick facts

Lead sponsor	Benha University
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	25 October 2020
Primary completion	25 December 2022
Estimated completion	30 December 2022
Sites	1 location across United Arab Emirates

Drugs / interventions tested

Brolucizumab-Dbll — full drug profile →

Conditions studied

Dystrophy, Retinal — all drugs for Dystrophy, Retinal →

Sponsor

Benha University

Who can join

Adults 18 to 50, any sex, with Dystrophy, Retinal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Dystrophy-Related macular neovascularization degeneration occur is a vision threatening condition.The investigators evaluate the efficacy of BEOVU intravitreal treatment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review).
Lu J, Ding J, Liu Z, Chen T. · · 2022 · cited 14× · PMID 34981814 · DOI 10.3892/ijo.2022.5302

Verify or expand the search:

Other Benha University trials

Trials by the same sponsor.

NCT07526675 — Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Prostate Cancer · NA · not yet recruiting
NCT07480031 — Determination of the Optimal Inspiratory Pressure to Decrease Incidence of Gastric Insufflation With Adequate Ventilatio · NA · not yet recruiting
NCT07465185 — Intrathecal Bupivacaine With or Without Dexmetomidine for Cesserian Delivery · Phase 2 · recruiting
NCT07467356 — Anterior Iliopsoas Space Block Versus PENG Block on Ease of Positioning for Spinal Anathesia in Patients Undergoing Hip · Phase 3 · recruiting
NCT07300787 — miRNA in Pediatric Gastritis · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04690062 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Benha University
Last refreshed: 30 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04690062.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing